Abstract
Background
This study validates the application of Systematized Nomenclature of Medicine second edition (SNOMED II) codes used to describe medical kidney biopsies in Denmark in encoded form, aiming to support robust epidemiological research on the causes, treatments and prognosis of kidney diseases.
Methods
Kidney biopsy reports from 1 January 1998 to 31 December 2018 were randomly extracted from the Danish National Patobank, using SNOMED codes. A 5% sample was selected, and nephrologists assessed the corresponding medical records, assigning each case the applied clinical diagnoses. Sensitivity, specificity, positive predictive values (PPV), negative predictive values and Cohen's kappa coefficient for the retrieved SNOMED codes were calculated.
Results
A total of 613 kidney biopsies were included. The primary clinical disease groups were glomerular disease (n = 368), tubulointerstitial disease (n = 67), renal vascular disease (n = 51), diabetic nephropathy (n = 51) and various renal disorders (n = 40). Several SNOMED codes were used to describe each clinical disease group and PPV for the combined SNOMED codes were high for glomerular disease (94%), diabetic nephropathy (85%) and systemic diseases affecting the kidney (96%). Conversely, tubulointerstitial disease (62%), renal vascular disease (60%) and other renal disorders (17%) showed lower PPV.
Conclusions
SNOMED codes have a high PPV for glomerular diseases, diabetic nephropathy and systemic diseases affecting the kidney, in which they could be applied for future epidemiological research.
This study validates the application of Systematized Nomenclature of Medicine second edition (SNOMED II) codes used to describe medical kidney biopsies in Denmark in encoded form, aiming to support robust epidemiological research on the causes, treatments and prognosis of kidney diseases.
Methods
Kidney biopsy reports from 1 January 1998 to 31 December 2018 were randomly extracted from the Danish National Patobank, using SNOMED codes. A 5% sample was selected, and nephrologists assessed the corresponding medical records, assigning each case the applied clinical diagnoses. Sensitivity, specificity, positive predictive values (PPV), negative predictive values and Cohen's kappa coefficient for the retrieved SNOMED codes were calculated.
Results
A total of 613 kidney biopsies were included. The primary clinical disease groups were glomerular disease (n = 368), tubulointerstitial disease (n = 67), renal vascular disease (n = 51), diabetic nephropathy (n = 51) and various renal disorders (n = 40). Several SNOMED codes were used to describe each clinical disease group and PPV for the combined SNOMED codes were high for glomerular disease (94%), diabetic nephropathy (85%) and systemic diseases affecting the kidney (96%). Conversely, tubulointerstitial disease (62%), renal vascular disease (60%) and other renal disorders (17%) showed lower PPV.
Conclusions
SNOMED codes have a high PPV for glomerular diseases, diabetic nephropathy and systemic diseases affecting the kidney, in which they could be applied for future epidemiological research.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | sfae203 |
| Tidsskrift | Clinical Kidney Journal |
| Vol/bind | 17 |
| Udgave nummer | 8 |
| Antal sider | 10 |
| ISSN | 2048-8505 |
| DOI | |
| Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:This study was supported by the Novo Nordisk Foundation with a Steno Collaborative Grant (NNF19OC0058900) and Herlev and Gentofte Hospital with a PhD Scholarship. The funding sources had no role in the design, conduct, analysis or reporting of the study.
Funding Information:
No potential conflicts of interest were reported by M.M., I.B., H.D., J.W.G., H.H., K.H., P.I., K.H.R., M.B.J., D.K., F.H.M., P.R., K.E.O., F.P. and K.D.S. T.K. reports honoraria for education and consultancy from AstraZeneca. R.B. reports honoraria for education and consultancy from AstraZeneca, Bayer, Mundipharma, Vifor and Boehringer Ingelheim. M.H. reports honoraria for advisory boards for AstraZeneca, Bayer, Boeringer Ingelheim, Vifor, GSK and Novo Nordisk A/S, and education for AstraZeneca, Boeringer Ingelheim and Novo Nordisk A/S outside the scope of this manuscript. D.H. reports research grant from Vifor Pharma and Gedeon Richter, and consultancy fees and lecture fees from UCB Nordic, GSK and AstraZeneca.
Publisher Copyright:
© The Author(s) 2024.